Biodefense Market

Biodefense Market Outlook

The Biodefense Market is valued at USD 18.3 Bn in 2026 and is projected to reach USD 26.1 Bn, growing at a CAGR of 5% by 2033.

The COVID-19 pandemic has caused the monumental loss of lives, and damage to the economy, social stability, and global security. In many ways, it has raised questions about the biological warfare, reigniting conversations around biodefense. To battle the biological threats, and rogue pathogenic attacks, countries are expected to expand their budgets for research and development of biodefense treatments, creating revenue generation opportunities in biodefense market. In the light of these current affairs, global demand for biodefense treatment is likely to witness an exponential spike in the next five years. This report throws light on how the growth of biodefense industry will unfold over the period of next few years.

• The market is slated for an impressive CAGR of 5% during the period of assessment
• Biodefense market size will attain the valuation of USD 26.1 Bn in 2033
• Anthrax remains a leading segment based on the type
• By end use, the military segment accounts for the largest share in biodefense industry
• North America spearheads on the back of favorable federal funding, whereas Asia Pacific’s will showcase the fastest growth through 2033

Increasing Prevalence of Infectious Diseases

Pacing developmental activities by governments, rise in prevalence of emerging threats, technological advancements, and focus on digital health collectively drive the growth of biodefense market. The market encompasses prophylactic, therapeutic, and diagnostic products for major biological, chemical and radiation threats, as well as those associated with emerging infectious diseases all over the world. Some of these conditions include anthrax, smallpox, botulism, chemical threats, radiation/nuclear exposures, and several emerging infectious diseases in various regions of the world. Such biodefense products are largely used for military purposes, civilians, and research institutes. This is expected to accelerate the progression of biodefense industry on a global level.

Mounting Demand in the Wake of Potential Bioterrorist Attacks

There is a possibility of reciprocal threats from emerging/re-emerging infectious diseases as well as accidentally released or deliberately used chemical, biological, radiological, or nuclear (CBRN) agents. The use of CBRN agents as threats has the potential of producing widespread public disruption. Repetitive and crucial attention focused on the likelihood of more attacks from chemical, biological, radiological, or nuclear agents has led the US government to expand resources and efforts into medical countermeasures research. Much of this work is directed by the National Institute of Allergy and Infectious Diseases component of the National Institutes of Health and the Centers for Disease Control and Prevention, along with other agencies including the US Department of Homeland Security.

Growing Geo-political Conflicts

The ascending threat of bioterrorism, coupled with rising geo-political tensions across the world have given every reason to nations to strengthen their arsenal. This will in turn boost biodefense market revenue. Governments from all corners are ramping up defense budgets with dedicated allocations to biological and chemical defense mechanisms. A multitude of geo-political escalations around the world and the recent pandemic have alerted defense strategists to rethink solutions. From the Middle East to South China Sea, many countries are locking horns to gain an upper hand geo-strategically.

Increase in mass awareness in relation to serious implications of biothreats have resulted in soaring demand for defensive systems and products. The growing emphasis on public health services towards development of diagnostics and procedures to detect biothreat agents is also driving biodefense treatment market. Technological advent in the discovery of pathogens in the fields of nanotechnology, forensics and biodefense-related drug development has helped market growth in recent times. As COVID-19 pandemic remains far from over, the already growing biodefense market has set the tone for an upward momentum in R&D activities.

Technological Advances, and Infrastructural Developments Eying Population Safeguarding

The market for biodefense countermeasures reflects continued awareness of the threat of global terror and biowarfare activity. The US Government (USG) remains the largest source of development and procurement backing for biopharmaceutical companies and academic institutions engaged in conducting biodefense research and developing vaccines targeting potential bioterror agents. The budget for annual expenditure by the US Department of Health and Human Services (HHS) for activities related to advanced development and procurement of medical countermeasures for chemical, biological, radiation, and nuclear threats to public health was approximately US$2 Bn until September 2021.

Growth Challenges

Demand for biodefense products is unfortunately uncertain due to the indeterminate scope, type, and magnitude of bioweapon attack in future. Developers of medical countermeasures are required to be dependent on government purchases which are subject to shifting political priorities, changing threat assessments thus presenting market uncertainties and limited profits. Major developmental and technical challenges along with certain regulatory, and market risks are thus anticipated to weaken commercial investments in biodefense products.

Overview of Key Segments

Based on the analysis of biodefense market by product type, the anthrax segment retains dominance, says the report. The ‘others’ segment that comprises viruses of influenza, cholera, plague, brucellosis, viral hemorrhagic fever, Ebola, Zika, tularemia, and food poisoning, is likely to demonstrate the fastest growth toward the end of forecast year. The report projects a CAGR of 6.2% for this segment during 2026 – 2033.

One the other hand, based on the end use, the military segment is expected to lead its way in biodefense market with an estimated revenue contribution of US$22.8 Bn by 2033. The fastest growth potential however is identified in the civil segment.

The US Retains Top Position with Considerable Federal Expenditure

Biodefense strategies from government departments of the United States, viz., HHS, BARDA, NIAID, and ASPR have been contributing toward the continued lead of the US in global biodefense market. The US ranks topmost and has Global Health Security (GHS) Index score of 75.9 showcasing the score for preparedness for threats with devastating potential. Sale of biodefense countermeasures to the US customers other than the United States Government (USG) is highly untapped.

Moreover, potential markets for the sale of biodefense countermeasures in addition to the US Government after meeting additional regulatory requirements include Ex US defense and public health agencies, multinational companies, and NGOs (such as WHO), healthcare institutions like hospitals and clinics, state and local governments, emergency responders- fire, police, and emergency medical personnels.

Europe, and Asia Pacific to Turn Lucrative

Europe is increasingly contributing to the biodefense market growth as the top European countries have scaled up their R&D expenditure amid the course of COVID-19 pandemic. On the other hand, emerging markets from Asia Pacific region are fast catching up with their global competitors with a measurable surge in R&D expenditure for development, and manufacturing of vaccines viz., COVID-19 vaccines, and other antitoxins for the different biological threats. Fairfield Market Research indicates that mature markets like Australia (GHS Index score 71.1), and Japan (GHS Index score 60.5) will continue to benefit from the well-laid down quality, and safety norms for development and production facilities.

The highly competitive market space has pushed leading players towards advanced technology adoption and strategic co-operations. In 2017, PharmAthene, and Altimmune merged to set up larger immunotherapeutic entity targeting infectious diseases. NightHawk biosciences completed acquisition of Elysus Therapeutics, Inc. which is developer of ANTHIM® (obiltoxaximab). a treatment for inhalation anthrax. ANTHIM® is approved for treatment of inhalation anthrax in the US, and Canada, and as Obiltoxaximab SFL in Europe and the UK. Fostering existing and establishing new partnerships, expansion of domestically based manufacturing capabilities and catalysing innovation across development pipeline for biodefense purpose are certain promising opportunities attracting new entrants in biodefense market.

Leading Market Players

Some of the key companies competing in the global biodefense market include 

• Emergent BioSolutions Inc.
• XOMA Corporation
• Altimmune Inc.
• Dynavax Technologies Corporation
• SIGA Technologies Inc.
• Elusys Therapeutics Inc.
• Ichor Medical Systems
• DynPort Vaccine Company
• Cleveland BioLabs Inc.
• Bavarian Nordic A/S
• Ology Bioservices Inc.
• Alnylam Pharmaceuticals Inc.
• GSK plc
• Sanofi (Sanofi Pasteur)
• PharmAthene Inc.

The Global Biodefense Market is Segmented as Below:

By Technology

• UV Light
• Gamma Radiation
• Cold Plasma
• Microwave Heating
• Others

By System

• Digital Biosurveillance Networks
• Early Warning Systems
• Biohazard Detection Systems
• AI-Assisted Surveillance System
• Biosensors
• Others

By End User

• Military Forces
• Homeland Security
• Hospitals & Clinics
• Pharmaceutical & Biotech Companies
• Virological Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa